Browsing Tag
ACCENT trial
3 posts
Amplia Therapeutics (ASX: ATX) stock faces its next big test as narmafotinib moves deeper into cancer trials
Find out how Amplia Therapeutics’ FY2026 report frames ASX: ATX, narmafotinib trials, cash runway and investor sentiment today!
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit
Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline.